Tag: bedside

Coolizi launches 2026 Cooling Ace personal evaporative cooler with energy-efficient operation and direct-to-consumer availability.

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Unprecedented patient demand reflects a deliberate strategy focused on access, advanced therapies and integrated researchDETROIT, June 22, 2026 /PRNewswire/ -- The Barbara Ann Karmanos Cancer...

Brigham nurses voted in record numbers on June 16 to authorize a one-day strike if MGB executives refuse to protect patient care and respect...

VRURC T009 3-in-1 Qi2 mag charger for Apple. 25W fast charge, dual cooling, retractable cable. Pre-order 62% off til June 20, 2026. 2y warranty.

BANGALORE, India, June 10, 2026 /PRNewswire/ -- ...

BANGALORE, India, June 10, 2026 /PRNewswire/ -- ...

The same clinician-approved animations from the Hx Heart app are now available online at HxHeart.com — free, instantly, with no download required.BERKELEY, Calif., June...

The new wearable recovery device pairs deep-kneading massage, layered warmth, and immersive audio to help ease neck tension

The new wearable recovery device pairs deep-kneading massage, layered warmth, and immersive audio to help ease neck tension

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company’s common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

ProBio and GCP ClinPlus today announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development...